StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report issued on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 1.9 %

NASDAQ EVOK opened at $4.14 on Friday. Evoke Pharma has a twelve month low of $3.54 and a twelve month high of $15.84. The business has a 50-day moving average price of $5.07 and a 200-day moving average price of $5.37. The firm has a market cap of $6.17 million, a price-to-earnings ratio of -0.38 and a beta of 0.16.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent filing with the Securities & Exchange Commission.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.